Coffee Drinking improves Survival in Advanced Colorectal Cancer: JAMA

The investigators found that in 1,171 patients treated for metastatic colorectal cancer, those who reported drinking two to three cups of coffee a day were likely to live longer overall, and had a longer time before their disease worsened, than those who didn't drink coffee. Participants who drank larger amounts of coffee - more than four cups a day - had an even greater benefit in these measures. The benefits held for both caffeinated and decaffeinated coffee.

After multivariable adjustment, each additional cup of coffee consumed daily was associated with a 7% reduction in mortality risk and a 5% reduction in disease progression risk, with a clear dose-response relationship. When analyzed by type of coffee, both caffeinated and decaffeinated coffee were significantly associated with lower mortality risk, while only decaf coffee was associated with lower progression risk.

The findings enabled investigators to establish an association, but not a cause-and-effect relationship, between coffee drinking and reduced risk of cancer progression and death among study participants. As a result, the study doesn't provide sufficient grounds for recommending, at this point, that people with advanced or metastatic colorectal cancer start drinking coffee on a daily basis or increase their consumption of the drink, researchers say.

"It's known that several compounds in coffee have antioxidant, anti-inflammatory, and other properties that may be active against cancer," says Dana-Farber's Chen Yuan, ScD, the co-first author of the study with Christopher Mackintosh, MLA, of the Mayo Clinic School of Medicine. "Epidemiological studies have found that higher coffee intake was associated with improved survival in patients with stage 3 colon cancer, but the relationship between coffee consumption and survival in patients with metastatic forms of the disease hasn't been known."

The new study drew on data from the Alliance/SWOG 80405 study, a phase III clinical trial comparing the addition of the drugs cetuximab and/or bevacizumab to standard chemotherapy in patients with previously untreated, locally advanced or metastatic colorectal cancer. As part of the trial, participants reported their dietary intake, including coffee consumption, on a questionnaire at the time of enrollment. Researchers correlated this data with information on the course of the cancer after treatment.

They found that participants who drank two to three cups of coffee per day had a reduced hazard for death and for cancer progression compared to those who didn't drink coffee. (Hazard is a measure of risk.) Those who consumed more than four cups per day had an even greater benefit.

"Although it is premature to recommend a high intake of coffee as a potential treatment for colorectal cancer, our study suggests that drinking coffee is not harmful and may potentially be beneficial," says Dana-Farber's Kimmie Ng, MD, MPH, senior author of the study.

"This study adds to the large body of literature supporting the importance of diet and other modifiable factors in the treatment of patients with colorectal cancer," Ng adds. "Further research is needed to determine if there is indeed a causal connection between coffee consumption and improved outcomes in patients with colorectal cancer, and precisely which compounds within coffee are responsible for this benefit."

For further reference

JAMA Oncology article